TW202216691A - 治療造血幹細胞移植後的移植物抗宿主病的方法 - Google Patents

治療造血幹細胞移植後的移植物抗宿主病的方法 Download PDF

Info

Publication number
TW202216691A
TW202216691A TW110126814A TW110126814A TW202216691A TW 202216691 A TW202216691 A TW 202216691A TW 110126814 A TW110126814 A TW 110126814A TW 110126814 A TW110126814 A TW 110126814A TW 202216691 A TW202216691 A TW 202216691A
Authority
TW
Taiwan
Prior art keywords
days
compound
formula
pharmaceutically acceptable
alkyl
Prior art date
Application number
TW110126814A
Other languages
English (en)
Chinese (zh)
Inventor
鄭翔玲
趙焰平
王紅軍
仲偉婷
李晶
趙靜
劉偉娜
Original Assignee
大陸商北京泰德製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商北京泰德製藥股份有限公司 filed Critical 大陸商北京泰德製藥股份有限公司
Publication of TW202216691A publication Critical patent/TW202216691A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110126814A 2020-07-22 2021-07-21 治療造血幹細胞移植後的移植物抗宿主病的方法 TW202216691A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010713637 2020-07-22
CN202010713637.0 2020-07-22

Publications (1)

Publication Number Publication Date
TW202216691A true TW202216691A (zh) 2022-05-01

Family

ID=79728482

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110126814A TW202216691A (zh) 2020-07-22 2021-07-21 治療造血幹細胞移植後的移植物抗宿主病的方法
TW112113471A TWI868660B (zh) 2020-07-22 2021-07-21 治療造血幹細胞移植後的移植物抗宿主病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112113471A TWI868660B (zh) 2020-07-22 2021-07-21 治療造血幹細胞移植後的移植物抗宿主病的方法

Country Status (11)

Country Link
US (1) US12702668B2 (cg-RX-API-DMAC7.html)
EP (1) EP4186508A4 (cg-RX-API-DMAC7.html)
JP (1) JP7803924B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230043891A (cg-RX-API-DMAC7.html)
CN (2) CN116322670A (cg-RX-API-DMAC7.html)
AU (1) AU2021313124A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001049A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186564A1 (cg-RX-API-DMAC7.html)
IL (1) IL299985A (cg-RX-API-DMAC7.html)
TW (2) TW202216691A (cg-RX-API-DMAC7.html)
WO (1) WO2022017412A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009568A (es) * 2009-03-09 2011-12-06 Surface Logix Inc Inhibidores de la rho cinasa.
RS63503B1 (sr) * 2012-10-05 2022-09-30 Kadmon Corporation Llc Inhibitori rho kinaze
EP3504204A4 (en) 2016-08-26 2020-05-27 Lycera Corporation INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP7311228B2 (ja) * 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
US10329282B2 (en) * 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法

Also Published As

Publication number Publication date
CA3186564A1 (en) 2022-01-27
JP2023535035A (ja) 2023-08-15
TWI868660B (zh) 2025-01-01
CN121846099A (zh) 2026-04-14
EP4186508A4 (en) 2024-10-16
BR112023001049A2 (pt) 2023-03-07
WO2022017412A1 (zh) 2022-01-27
AU2021313124A1 (en) 2023-03-09
CN116322670A (zh) 2023-06-23
EP4186508A1 (en) 2023-05-31
JP7803924B2 (ja) 2026-01-21
US12702668B2 (en) 2026-08-11
US20230285393A1 (en) 2023-09-14
IL299985A (en) 2023-03-01
TW202327609A (zh) 2023-07-16
KR20230043891A (ko) 2023-03-31

Similar Documents

Publication Publication Date Title
TWI804743B (zh) 治療特發性肺纖維化的方法
KR102705376B1 (ko) 화학적 화합물
KR101483831B1 (ko) 대장염 치료용 조성물 및 방법
WO2020177587A1 (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法
EA030068B1 (ru) Соединения-ингибиторы аутотаксина
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
JP7665529B2 (ja) ジアミノピリミジン化合物を使用することによって咳を治療する方法
HK40086216A (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
WO2022135534A1 (zh) 取代的含氮双环化合物及其用途
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
TW202327608A (zh) 治療病毒感染的方法
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
HK40063619B (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
HK40063168B (en) Method for treating cough by using diaminopyrimidine compound
WO2026096924A1 (en) Methods for the treatment of hematological malignancies